New drug CTX-187 takes aim at stubborn bacterial infections
Disease control
Recruiting now
This first-in-human trial tests an experimental drug called CTX-187 for safety and tolerability. It starts with healthy volunteers to assess single and multiple doses, then moves to patients with bronchiectasis who have a chronic Pseudomonas infection. The goal is to see if the d…
Phase: PHASE1 • Sponsor: Centauri Therapeutics Limited • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC